Summary
Multiple Myeloma (MM) is characterised by the accumulation of malignant plasma cells in the bone marrow producing a monoclonal immunoglobulin. The standard conventional therapy is the combination of melphalan and prednisone resulting in a response rate of 40%–60% and in a median survival time of approximately 3 years. In order to improve the therapeutic efficacy various combination regimens have been tested. Most randomized trials have frailed to show a significant improvement in survival time when combination chemotherapy is used instead of melphalan with or without prednisone. The benefit of maintenance therapy with interferon-alpha has been demonstrated. The toxicity of interferon-alpha, which may reduce the quality of life, should be considered. Recently, myeloma-treatment has been modified. High-dose chemotherapy accompanied by hematopoietic stem-cell support via autologous transplant is recommended up to the age of 65–70 years. First results from a French study comparing single versus double autologous transplantation have shown a benefit in terms of event-free survival for the sequential approach. Vaccinations as an adoptive immuntherapy to treat minimal residual disease are under way. The mortality rate of allogeneic transplantation of hematopoietic stem cells has been reduced in the last 5 years. The use of reduced conditioning regimens or the partial depletion of T cells in peripheral blood stem cell transplants in an effort to decrease transplant related mortality are promising approaches. Thalidomide and its derivates are a new class of agents with independent anti-tumour activity in MM. Encouraging results with this antiangiogenic therapy in phase II trials have been reported. Supportive therapies, such as the treatment of anaemia with erythropoietin, the management of renal failure and the use of bisphosphonates, improve the life quality of MM patients.
Similar content being viewed by others
References
Alexanian R, Dreicer R. Chemotherapy for multiple myeloma. Cancer, 1984, 53: 583–588.
Samson D. Principles of chemotherapy and radiotherapy. In: Multiple Myeloma, eds. Gahrton G, Durie GM. Arnold, London, Sydney, Auckland, 1996. 108–129.
Gregory WM, Richards MA, Malpas JS. Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: An overview of published trials. J Clin Oncol, 1992, 10: 334–342.
Wheatley K. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: An overview of 6 633 patients from 27 randomised trials. J Clin Oncol, 1998, 16: 3832–3842.
Barlogie B, Smith L, Alexanian R. Effective treatment of advanced multiple myeloma resistant to alkylating agents. New Engl J Med, 1984, 310: 1353–1356.
Fritz E, Ludwig H. Interferon-alpha treatment in multiple myeloma: meta-analysis of 30 randomised trials among 3948 patients. Ann Oncol, 2000, 11: 615.
Ludwig H, Fritz E, Neuda J, et al. Patients preferences for interferon alpha in multiple myeloma. J Clin Oncol, 1997, 15: 1672–1679.
Attal M, Harousseau JL, Stoppa AM, et al. A Prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med, 1999, 335: 91–97.
Barlogie B, Jagannath S, Desikan KR, et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood, 1999, 93: 55–65.
Lenhoff S, Hjorth M, Holmberg E, et al. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Blood, 2000, 95: 6–11.
Siegel DS, Desikan KR, Mehta J, et al. Age is not a prognostic factor variable with autotransplants for multiple myeloma. Blood, 1999, 93: 51–54.
Moreau P, Facon T, Attal M, et al. Comparison of 200mg/m2 melphalan and 8 Gy total body irradiation plus 140mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma. Final analysis of the IFM 95-02 randomized trial. Blood, 2002, 99: 731–735.
Attal M, Harousseau JL. Autograft and multipe myeloma: experience of the IMF. Bull Cancer, 2001, 88: 888–892.
Goldschmidt H, Bouko Y, Bourhis JH, et al. CD34+ selected PBPCT results in an increased infective risk without prolongation of event free survival in newly diagnosed myeloma: a randomised study from the EBMT. Blood, 2000, 96: 558a (abstract).
Attal M, Harousseau JL, Facon T. Single versus double transplant in myeloma: a randomized trial of the IFM. Proceed VIII th International Myeloma Workshop. 2001, S15: 28 (abstract).
Kyle RA. Current therapy of multiple myeloma. Intern Med, 2002, 41: 175–180.
Pfeiffer S, Gooding R, Apperley J, et al. Dendritic cells generated from the blood of patients with multiple myeloma are phenotypically and functionally identical to those similarly produced from healthy donors. Br J Haematol, 1997, 98: 973–982.
Gahrton G, Svensson H, Cavo M, et al. Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: A comparision between transplants performed 1983–1993 and 1994–1998 at Europe Group for Blood and Bone Marrow Transplantation centers. Brit J Haematol, 2002. 209–216.
Lalancette MRK, Sydlo R, Mackinnon S, et al. Excellent outcome of non-myeloablative stem cell transplant (NMSCT) for good risk myeloma: the European Group for Blood and Marrow Transplantation (EBMT) experience. In: American Society of Hematology (ASH); 2000: Blood; 2000, abstract.
Lokhorst HM, Schattenberg A, Cornelissen JJ, et al. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood, 1997, 90: 4206–4211.
Corradini P, Tarella C, Olivieri A, et al. Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies. Blood, 2002, 99: 75–82.
Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med, 1999, 341: 1656–1671.
Neben K, Moehler T, Benner A, et al. Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma. Clincial Cancer Research (in press).
Moehler TM, Neben K, Benner A, et al. Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy. Blood, 2001, 15: 3846–3848.
Garton JP, Gertz MA, Witzig TE, et al. Epoetin alfa for the treatment of anemia of multiple myeloma. Achr Intern Med, 1995, 155: 2069–2074.
Oken MM, Pomeroy C, Weisdorf D, et al. Prophylactic antibiotics for the prevention of early infection in multiple myeloma. Am J Med, 1996, 100: 624–628.
Djulbegovic B, Wheatley K, Ross J, et al. Bisphosphonates ion multiple myeloma. Chochr. Database Syst Rev, 2001, 9: CD003188.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
H., G., F. W., C., Th., M. et al. Therapy of multiple myeloma. Chin. -Ger. J. Clin. Oncol. 1, 141–144 (2002). https://doi.org/10.1007/BF02851708
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF02851708